Company / Capital Expenditures
CUMBERLAND PHARMACEUTICALS INC Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$97.9K
FY2025
5-year range
$97.9K / $281.3K
FY2021-FY2025
Trend
-65.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $97,903 in FY2025 to $281,268 in FY2024.
Based on SEC 10-K filings.
$97,903 in FY2025 with a 5-year CAGR of -7.0%.
Declined from $102,148 to $97,903 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -1.8%
- 5-Year CAGR
- -7.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -7.0%, indicating a declining trend.
- In FY2025, capital expenditures decreased 65.2% year-over-year.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $97.9K | -65.2% |
| FY2024 | $281.3K | +175.4% |
| FY2023 | $102.1K | -1.3% |
| FY2022 | $103.5K | -57.9% |
| FY2021 | $246.2K | +74.8% |
| FY2020 | $140.8K | -42.8% |
| FY2019 | $246.2K | +88.1% |
| FY2018 | $130.9K | -8.5% |
| FY2017 | $143.0K | -12.4% |
| FY2016 | $163.3K | +67.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026